Prevalence of Dyslipidemia and the Role of ApoB and hsCRP in Acute Myocardial Infarction: A Comprehensive Analysis: Dyslipidemia, ApoB, and hsCRP in Acute Myocardial Infarction

Azfar Farogh; Zafar Iqbal; Muhammad Affan Qaiser; Bushra Hussain; Syeda Abeer Fatima; Naheed Akhter

doi:10.54393/pjhs.v5i12.2520

Authors

Azfar Farogh Department of Medicine, Shahida Islam Medical College, Lodhran, Pakistan
Zafar Iqbal Department of Cardiology, Shahida Islam Medical College, Lodhran, Pakistan
Muhammad Affan Qaiser Department of Gastroenterology, Shahida Islam Teaching Hospital, Lodhran, Pakistan
Bushra Hussain Department of Physiology, Services Institute of Medical Sciences, Lahore, Pakistan
Syeda Abeer Fatima Department of Physiology, Services Institute of Medical Sciences, Lahore, Pakistan
Naheed Akhter Combined Military Hospital, Institute of Medical Sciences, Bahawalpur, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i12.2520

Keywords:

Dyslipidemia, Apolipoprotein B, Highly Sensitive C-Reactive Protein, Acute Myocardial Infarction

Abstract

Dyslipidemia significantly contributes to AMI, with ApoB and hsCRP offering potential for improved risk prediction. Objective: To determine the prevalence of dyslipidemia and the role of ApoB and hsCRP in acute myocardial infarction in patients presenting to a tertiary care hospital in Lodhran, Punjab. Methods: A cross-sectional study was conducted at the Department of Medicine, Shahida Islam Medical College, Lodhran, from May 2023 to November 2023. A total of 187 AMI patients aged 30–90 years were included using non-probability consecutive sampling. Data were collected using structured clinical history forms and laboratory analysis of lipid profiles, ApoB, and hsCRP levels. Dyslipidemia was defined using standard lipid cutoff values. Statistical analysis was performed using SPSS version 25.0, employing Chi-square and logistic regression to explore associations and predictors of dyslipidemia, with a significance level of p < 0.05. Results: Dyslipidemia was highly prevalent, affecting 74.9% of patients. Hypertension was significantly associated with dyslipidemia (OR = 2.049, p = 0.042), indicating a potential need for combined management strategies. ApoB and hsCRP levels did not show significant differences between dyslipidemic and non-dyslipidemic patients, though total cholesterol and LDL levels were significantly higher in the dyslipidemic group (p < 0.001). Conclusions: This study revealed a high prevalence of dyslipidemia in AMI patients, with hypertension as a key predictor. While ApoB and hsCRP were not significant discriminators, their roles in cardiovascular risk assessment may complement traditional lipid profiles, supporting personalized management strategies to reduce cardiovascular risk.

References

Arvanitis M and Lowenstein CJ. Dyslipidemia. Annals of internal medicine. 2023 Jun; 176(6): ITC81-96. doi: 10.7326/AITC202306200. DOI: https://doi.org/10.7326/AITC202306200

Krintus M, Kozinski M, Stefanska A, Sawicki M, Obonska K, Fabiszak T et al. Value of C‐reactive protein as a risk factor for acute coronary syndrome: A comparison with apolipoprotein concentrations and lipid profile. Mediators of Inflammation. 2012; 2012(1): 419804. doi: 10.1155/2012/419804. DOI: https://doi.org/10.1155/2012/419804

Leela P. Study of Serum Lipoprotein (a), Apolipoprotein B, hsCRP and Lipid Profile in Ischemic Heart Disease. [Doctoral dissertation]. Rajiv Gandhi University of Health Sciences (India). 2014.

Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. European Heart Journal. 2021 Nov; 42(42): 4324-32. doi: 10.1093/eurheartj/ehab432. DOI: https://doi.org/10.1093/eurheartj/ehab432

Higashi Y. Endothelial Function in dyslipidemia: roles of LDL-cholesterol, HDL-cholesterol and triglycerides. Cells. 2023 May; 12(9): 1293. doi: 10.3390/cells12091293. DOI: https://doi.org/10.3390/cells12091293

Rasouli M, Kiasari AM. Interactions of serum hsCRP with apoB, apoB/AI ratio and some components of metabolic syndrome amplify the predictive values for coronary artery disease. Clinical biochemistry. 2006 Oct; 39(10): 971-7. doi: 10.1016/j.clinbiochem.2006.07.003. DOI: https://doi.org/10.1016/j.clinbiochem.2006.07.003

Lin H, Wang L, Liu Z, Long K, Kong M, Ye D et al. Hepatic MDM2 Causes Metabolic Associated Fatty Liver Disease by Blocking Triglyceride‐VLDL Secretion via ApoB Degradation. Advanced Science. 2022 Jul; 9(20): 2200742. doi: 10.1002/advs.202200742. DOI: https://doi.org/10.1002/advs.202200742

Chyu KY, Zhao X, Zhou J, Dimayuga PC, Lio NW, Cercek B et al. Immunization using ApoB-100 peptide-linked nanoparticles reduces atherosclerosis. JCI Insight. 2022 Jun; 7(11). doi: 10.1172/jci.insight.149741. DOI: https://doi.org/10.1172/jci.insight.149741

Carrero JJ, Andersson Franko M, Obergfell A, Gabrielsen A, Jernberg T. hsCRP level and the risk of death or recurrent cardiovascular events in patients with myocardial infarction: a healthcare‐based study. Journal of the American Heart Association. 2019 Jun; 8(11): e012638. doi: 10.1161/JAHA.119.012638. DOI: https://doi.org/10.1161/JAHA.119.012638

Johannesen CD, Mortensen MB, Langsted A, Nordestgaard BG. ApoB and Non‐HDL Cholesterol Versus LDL Cholesterol for Ischemic Stroke Risk. Annals of Neurology. 2022 Sep; 92(3): 379-89. doi: 10.1002/ana.26425. DOI: https://doi.org/10.1002/ana.26425

Kayani T, Ahmad B, Chang RS, Qian F, Sahinoz M, Rehan MW et al. Beyond Statins: Novel Lipid-Lowering Agents for Reducing Risk of Atherosclerotic Cardiovascular Disease. Pharmacoepidemiology. 2024 Mar; 3(1): 117-68. doi: 10.3390/pharma3010009. DOI: https://doi.org/10.3390/pharma3010009

Khan HA, Alhomida AS, Sobki SH. Lipid profile of patients with acute myocardial infarction and its correlation with systemic inflammation. Biomarker Insights. 2013 Jan; 8: BMI-S11015. doi: 10.4137/BMI.S11015. DOI: https://doi.org/10.4137/BMI.S11015

Ali SN, Bashir M, Sherwani M. Pattern of dyslipidemia in young patients with acute ST elevation myocardial infarction. Journal Sheikh Zayed Medical College. 2016; 7(3): 998-1001.

Iqbal MZ, Dogar LA, Rafiq Z. Association of Dyslipidemia with Acute Myocardial Infarction (CAD). Lateral. 2012; 25(10): 35.

Morofuji Y, Nakagawa S, Ujifuku K, Fujimoto T, Otsuka K, Niwa M et al. Beyond lipid-lowering: effects of statins on cardiovascular and cerebrovascular diseases and cancer. Pharmaceuticals. 2022 Jan; 15(2): 151. doi: 10.3390/ph15020151. DOI: https://doi.org/10.3390/ph15020151

Gupta MD, Girish MP, Sarkar PG, Gupta A, Kategari A, Bansal A et al. Role of ApoE gene polymorphism and nonconventional biochemical risk factors among very young individuals (aged less than 35 years) presenting with acute myocardial infarction. Indian Heart Journal. 2018 Dec; 70: S146-56. doi: 10.1016/j.ihj.2018.08.013. DOI: https://doi.org/10.1016/j.ihj.2018.08.013

Pham-Thi NN, Tran-Thi TL, Duong HQ, Do HL, Huynh TC, Le TS et al. Comprehensive Analysis of Demographic, Clinical, and Genetic Characteristics in Acute Myocardial Infarction Patients. F1000Research. 2024 Aug; 13(937): 937. doi: 10.12688/f1000research.154230.1. DOI: https://doi.org/10.12688/f1000research.154230.1

Talviste G, Leinsalu M, Ross P, Viigimaa M. Lipid-Lowering Treatment Gaps in Patients after Acute Myocardial Infarction: Using Global Database TriNetX. Medicina. 2024 Sep; 60(9): 1433. doi: 10.3390/medicina60091433. DOI: https://doi.org/10.3390/medicina60091433

Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E et al. Lipoprotein (a) reduction in persons with cardiovascular disease. New England Journal of Medicine. 2020 Jan; 382(3): 244-55. doi: 10.1056/NEJMoa1905239. DOI: https://doi.org/10.1056/NEJMoa1905239

Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM et al. 2018 Guidelines for the management of dyslipidemia in Korea. Journal of Lipid and Atherosclerosis. 2019 Sep; 8(2): 78-131. doi: 10.12997/jla.2019.8.2.78. DOI: https://doi.org/10.12997/jla.2019.8.2.78